CN107625756B - 1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 - Google Patents
1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN107625756B CN107625756B CN201710796452.9A CN201710796452A CN107625756B CN 107625756 B CN107625756 B CN 107625756B CN 201710796452 A CN201710796452 A CN 201710796452A CN 107625756 B CN107625756 B CN 107625756B
- Authority
- CN
- China
- Prior art keywords
- cancer
- cell
- hexylene glycol
- pancreas
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 17
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 30
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 30
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 10
- 201000001441 melanoma Diseases 0.000 claims abstract description 10
- 201000005202 lung cancer Diseases 0.000 claims abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 10
- 238000011161 development Methods 0.000 abstract description 6
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 230000003993 interaction Effects 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 33
- 208000008443 pancreatic carcinoma Diseases 0.000 description 12
- 238000005191 phase separation Methods 0.000 description 11
- 201000002528 pancreatic cancer Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 238000010609 cell counting kit-8 assay Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 108010087230 Sincalide Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 229940051250 hexylene glycol Drugs 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N hexylene glycol Natural products CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710796452.9A CN107625756B (zh) | 2017-09-06 | 2017-09-06 | 1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710796452.9A CN107625756B (zh) | 2017-09-06 | 2017-09-06 | 1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107625756A CN107625756A (zh) | 2018-01-26 |
CN107625756B true CN107625756B (zh) | 2019-10-25 |
Family
ID=61100154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710796452.9A Expired - Fee Related CN107625756B (zh) | 2017-09-06 | 2017-09-06 | 1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107625756B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111544423B (zh) * | 2020-06-30 | 2022-10-11 | 南通大学 | 1,6-己二醇在治疗血管生成过多造成的疾病方面的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829084A (en) * | 1983-09-29 | 1989-05-09 | Sterling Drug Inc. | Method for treating malignant conditions |
-
2017
- 2017-09-06 CN CN201710796452.9A patent/CN107625756B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829084A (en) * | 1983-09-29 | 1989-05-09 | Sterling Drug Inc. | Method for treating malignant conditions |
Also Published As
Publication number | Publication date |
---|---|
CN107625756A (zh) | 2018-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Piperlongumine selectively kills hepatocellular carcinoma cells and preferentially inhibits their invasion via ROS-ER-MAPKs-CHOP | |
Frieboes et al. | Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy | |
CN105111271A (zh) | 一种熊果酸-阿司匹林偶联物及其在制备预防肿瘤转移中药物的应用 | |
CN107625756B (zh) | 1,6-己二醇或其衍生物在制备抗肿瘤药物中的应用 | |
CN103179967A (zh) | 抗肿瘤药物组合物 | |
CN103933048B (zh) | 一种熊果酸衍生物在制备预防和治疗肿瘤转移药物中的应用 | |
CN104586873B (zh) | 木蝴蝶苷a在制备治疗癌症药物中的应用 | |
CN106188209B (zh) | 一种兼具抗肿瘤和抗肿瘤转移活性的二甲双胍偶联物及其应用 | |
CN102688493A (zh) | 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用 | |
CN105963306B (zh) | 一种具有协同抗肿瘤转移活性的药物组合物 | |
US20190183893A1 (en) | Low dose of sildenafil as an antitumor drug | |
CN102688489B (zh) | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN105012307B (zh) | Imb5046化合物在制备抗肿瘤药物中的用途 | |
CN113329745A (zh) | 一种有效抗恶性肿瘤的药物组合物及其应用 | |
CN102688228B (zh) | 含有芹菜素及芹菜素类衍生物和冬凌草甲素及冬凌草甲素类衍生物的药物组合物及其应用 | |
CN105878270A (zh) | 低氘水作为肿瘤多药耐药逆转剂的应用 | |
CN108864037A (zh) | Trpml1特异性激动剂、其作为自噬抑制剂及制备治疗肿瘤药物的应用、药物组合物 | |
CN107412206B (zh) | 1,6-己二醇或其衍生物在制备抗血液肿瘤药物中的应用 | |
US9655875B2 (en) | Method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene | |
CN107955024B (zh) | 以三((二苯膦)亚甲基)胺为配体的十五核银簇合物及其合成方法和抗肿瘤应用 | |
CN105769863A (zh) | 替拉那韦在抗癌症药物中的应用及抗癌症药物 | |
CN101317835A (zh) | 斑蝥素及其衍生物在制备肿瘤化疗增敏药物中的应用 | |
CN105801658A (zh) | 甜甙及其类似物的制备及作为stat3、erk信号通路靶位点药物在抗肿瘤中的应用 | |
CN109091471A (zh) | 大果桉醛b用于制备治疗人结肠癌的药物的用途 | |
CN102688490A (zh) | 含有吴茱萸碱及吴茱萸碱类衍生物和Bc1-2抑制剂的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201015 Address after: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee after: Center for technology transfer, Nantong University Address before: 226019 Jiangsu city of Nantong province sik Road No. 9 Patentee before: NANTONG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201215 Address after: 8319 Yanshan Road, Bengbu City, Anhui Province Patentee after: Bengbu Lichao Information Technology Co.,Ltd. Address before: 226019 No.205, building 6, Nantong University, No.9, Siyuan Road, Nantong City, Jiangsu Province Patentee before: Center for technology transfer, Nantong University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210511 Address after: 226600 169 Li Fa FA Road, Chengdong Town, Haian County, Nantong, Jiangsu Patentee after: HAI'AN BAIYOU MATRIX BIOENGINEERING Co.,Ltd. Address before: 8319 Yanshan Road, Bengbu City, Anhui Province Patentee before: Bengbu Lichao Information Technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191025 |